| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/16/2013 | US8486374 Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
| 07/16/2013 | CA2754589C Steroid compound |
| 07/16/2013 | CA2741575C Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| 07/16/2013 | CA2741412C Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| 07/16/2013 | CA2719440C Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of respiratory illness in muscular dystrophy |
| 07/16/2013 | CA2711508C Proline analogs as ligands for cannabinoid receptors |
| 07/16/2013 | CA2707067C Clear ophthalmic solution comprising latanoprost as active ingredient |
| 07/16/2013 | CA2705474C O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates |
| 07/16/2013 | CA2699674C 5-ht7 receptor antagonists |
| 07/16/2013 | CA2697167C Benzimidazole derivatives used as fxr agonists |
| 07/16/2013 | CA2673615C Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| 07/16/2013 | CA2658884C Metal/thiol biocides |
| 07/16/2013 | CA2650627C Pieridinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 07/16/2013 | CA2644841C Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia |
| 07/16/2013 | CA2620026C Method for production of single- and multi-layer microcapsules |
| 07/16/2013 | CA2615563C Compositions and methods for controlling infections |
| 07/16/2013 | CA2604584C Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder |
| 07/16/2013 | CA2590048C Cytosine nucleoside analogs and isoflavones and uses thereof |
| 07/16/2013 | CA2583983C Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 07/16/2013 | CA2581485C Methods and compositions for treating hyperglycemic, hyperlipidemic, or hyperinsulinemic disorders |
| 07/16/2013 | CA2577222C Isoindoline compounds and methods of making and using the same |
| 07/16/2013 | CA2569826C Substituted 2-alkyl quinazolinone derivatives as parp inhibitors |
| 07/16/2013 | CA2569664C Lipid encapsulated interfering rna |
| 07/16/2013 | CA2566793C A novel dosage form |
| 07/16/2013 | CA2558582C Stabilised supersaturated solids of lipophilic drugs |
| 07/16/2013 | CA2551121C Crosslinked hyaluronic acid compositions for tissue augmentation |
| 07/16/2013 | CA2547645C Use of rotigotine for the treatment or prevention of dopaminergic neuron loss |
| 07/16/2013 | CA2544352C Crystalline anhydrate with anticholinergic effect |
| 07/16/2013 | CA2540159C Extended release venlafaxine formulation |
| 07/16/2013 | CA2537257C Fexofenadine polymorphs and processes of preparing the same |
| 07/16/2013 | CA2535029C Pharmaceutical compositions and methods for accelerating wound healing |
| 07/16/2013 | CA2534094C Glycosidase inhibitors and methods of synthesizing same |
| 07/16/2013 | CA2526007C Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 07/16/2013 | CA2514988C Sulfonic acids, their derivatives and pharmaceutical compositions containing them |
| 07/16/2013 | CA2507348C Real time methylumbelliferone-based assay |
| 07/16/2013 | CA2493888C Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications |
| 07/16/2013 | CA2486106C Compounds and methods for inhibiting selectin-mediated function |
| 07/16/2013 | CA2485592C Anti tubercular drug: compositions and methods |
| 07/16/2013 | CA2483120C Polymeric adhesive transdermal patch comprising rotigotine for treatment of restless leg syndrome |
| 07/16/2013 | CA2480925C Compositions comprising retinoids and nondenatured botanical extracts having trypsin-inhibiting activity for treating skin conditions |
| 07/16/2013 | CA2477283C Vascular therapeutic methods and compositions involving the reduction or prevention of c-jun mediated processes |
| 07/16/2013 | CA2476890C Subtilisin carlsberg proteins with reduced immunogenicity |
| 07/16/2013 | CA2464656C Spray drying methods and compositions thereof |
| 07/16/2013 | CA2458476C Photoreactive compounds and compositions |
| 07/16/2013 | CA2452977C Facially amphiphilic polymers as anti-infective agents |
| 07/16/2013 | CA2448348C Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 07/16/2013 | CA2425665C Coated implantable medical device |
| 07/16/2013 | CA2425486C Flea peritrophin nucleic acid molecules, proteins and uses thereof |
| 07/16/2013 | CA2330231C Composition and method for modulating dendritic cell-t cell interaction |
| 07/16/2013 | CA2253441C Glycoprotein hormone superagonists |
| 07/16/2013 | CA2226624C Methods for treatment of allergic asthma |
| 07/15/2013 | CA2818075A1 Reducible self-assembled micelle drug delivery systems |
| 07/11/2013 | WO2013103993A1 Therapeutic compounds and related methods of use |
| 07/11/2013 | WO2013103973A1 Carbamate compounds and of making and using same |
| 07/11/2013 | WO2013103967A1 Allosteric modulators of cb1 cannabinoid receptors |
| 07/11/2013 | WO2013103966A1 Methods for the treatment of multiple sclerosis and other demyelinating disorders |
| 07/11/2013 | WO2013103958A1 Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
| 07/11/2013 | WO2013103931A1 Substituted 1-benzylindolin-2-one analogs as positive allosteric modulators of muscarinic acetylcholine m1 receptors |
| 07/11/2013 | WO2013103919A2 Compositions and methods for treating metabolic disorders |
| 07/11/2013 | WO2013103902A1 Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
| 07/11/2013 | WO2013103874A1 Skin lightening compositions |
| 07/11/2013 | WO2013103873A1 Chiral compounds, compositions, products and methods employing same |
| 07/11/2013 | WO2013103867A1 Benzenesulfonamide derivative for use in the treatment of diabetic neuropathy |
| 07/11/2013 | WO2013103842A1 Methods of reducing risk of cardiovascular disease |
| 07/11/2013 | WO2013103840A1 Anti-cancer composition and method utilizing 3-bp and liposomal reduced glutathione |
| 07/11/2013 | WO2013103836A2 Methods of treating cancer |
| 07/11/2013 | WO2013103826A1 Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation |
| 07/11/2013 | WO2013103795A1 Bis (thiohydrazide amide) compounds for treating cancers |
| 07/11/2013 | WO2013103780A1 Compositions and methods to boost endogenous ros production from bacteria |
| 07/11/2013 | WO2013103760A1 Compositions, methods of use, and methods of treatment |
| 07/11/2013 | WO2013103738A1 Napthalene acetic acid derivatives against hiv infection |
| 07/11/2013 | WO2013103724A1 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids |
| 07/11/2013 | WO2013103687A2 Treatment of heart failure and sudden cardiac death |
| 07/11/2013 | WO2013103668A1 Formulations for enhanced bioavailability of zanamivir |
| 07/11/2013 | WO2013103632A1 Double-stranded rna compounds to casp2 and uses thereof |
| 07/11/2013 | WO2013103601A1 Carbocyclic nucleosides and their pharmaceutical use and compositions |
| 07/11/2013 | WO2013103567A2 Methods of blocking platelet activation during extracorporeal circulation using cangrelor |
| 07/11/2013 | WO2013103531A1 A method for treating lyme disease |
| 07/11/2013 | WO2013103467A1 Interfering rna delivery system and uses thereof |
| 07/11/2013 | WO2013103434A1 Methods and compositions to protect aquatic invertebrates from disease |
| 07/11/2013 | WO2013103390A1 Extended-release formulation for reducing the frequency of urination and method of use thereof |
| 07/11/2013 | WO2013103389A1 Delayed-release formulation for reducing the frequency of urination and method of use thereof |
| 07/11/2013 | WO2013103384A1 Biguanide compositions and methods of treating metabolic disorders |
| 07/11/2013 | WO2013103378A1 Dexmedetomidine premix formulation |
| 07/11/2013 | WO2013103357A1 Extended-release formulation for reducing the frequency of urination and method of use thereof |
| 07/11/2013 | WO2013103356A1 Delayed release formulation for reducing the frequency of urination and method of use thereof |
| 07/11/2013 | WO2013103318A1 Solid nicotine-comprising dosage form with reduced organoleptic disturbance |
| 07/11/2013 | WO2013103317A1 Quinoline compounds which are anti-angiogenic integrin alpha5 betal inhibitors for use in the treatment of fibrosis or fibrosis-related diseases |
| 07/11/2013 | WO2013103262A1 Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof |
| 07/11/2013 | WO2013103250A1 Composition comprising tauroursodeoxycholic acid |
| 07/11/2013 | WO2013103249A1 High-efficiency nanoparticle-type double-helical oligo-rna structure and method for preparing same |
| 07/11/2013 | WO2013103155A1 Agent for reduction of sensory irritation |
| 07/11/2013 | WO2013103150A1 Acid adduct salt of substituted pyridine compound |
| 07/11/2013 | WO2013103148A1 Collateral blood circulation development promoter |
| 07/11/2013 | WO2013103089A1 Culture method for maintenance and propagation of stem cells by lysophospholipid signal control |
| 07/11/2013 | WO2013102936A1 N-(3-((diethylamino) methyl)-4-hydroxyphenyl)-n-(quinolin-4-yl) sulfonamides for the treatment of tuberculosis and process of preparation thereof |
| 07/11/2013 | WO2013102929A1 Novel compounds for treatment of diabetes, obesity or related disorders |
| 07/11/2013 | WO2013102920A1 Stable lyophilized formulation of bendamustine |
| 07/11/2013 | WO2013102919A1 Polymorphic forms of ivabradine hydrochloride |
| 07/11/2013 | WO2013102907A1 Ophthalmic composition |